-
1 Comment
CytoTools AG is currently in a long term downtrend where the price is trading 9.8% below its 200 day moving average.
From a valuation standpoint, the stock is 3987.5% more expensive than other stocks from the Financial Services sector with a price to sales ratio of 1814.7.
Based on the above factors, CytoTools AG gets an overall score of 0/5.
| ISIN | DE000A0KFRJ1 |
|---|---|
| Sector | Healthcare |
| Industry | Biotechnology |
| CurrencyCode | EUR |
| Exchange | F |
| Market Cap | 12M |
|---|---|
| Dividend Yield | 0.0% |
| Beta | 1.47 |
| PE Ratio | None |
| Target Price | 34.85 |
bioXXmed AG, an investment company, invests in biotechnology or medical technology companies with equity or debt capital. It engages in the development of products for the diagnosis, alleviation, or cure of diseases through investments. The company was formerly known as CytoTools AG and changed its name to bioXXmed AG in September 2022. The company was founded in 2000 and is based in Darmstadt, Germany.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for T5O.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
